Evidence map›Paper›PMID 39051331›Full record

ArticleAntibodies (Basel, Switzerland)2024

NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for

Marta Freitas Monteiro, Maria Papaserafeim, Matteo Andreani, Aline Réal, Athanasios Kouklas, Daniela Reis Galvão, Jörg D Seebach, Gisella L Puga Yung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Freitas MonteiroLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.
Maria PapaserafeimLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.
Matteo AndreaniLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.
Aline RéalLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.ORCID 0000-0002-9437-4411
Athanasios KouklasLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.ORCID 0000-0002-3282-0674
Daniela Reis GalvãoLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.
Jörg D SeebachLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.ORCID 0000-0001-5748-4577
Gisella L Puga YungLaboratory of Translational Immunology, Department of Medicine, Division of Immunology and Allergology, University Hospitals Geneva, Medical Faculty, CH-1211 Geneva, Switzerland.ORCID 0000-0002-2283-7798

Funding

Private Foundation n/aSwiss National Science Foundation 10030_201231
6 · The paper itself

Abstract

Natural killer (NK) cells play an important role in the surveillance of viral infections and cancer. NK cell antibody-dependent cellular cytotoxicity (ADCC) and direct cytotoxicity are mediated by the recognition of antibody-coated target cells through the Fc gamma receptor IIIA (FcγRIIIa/CD16) and by ligands of activating/inhibitory NK receptors, respectively. Allelic variants of the

Indexed as

ADCCCD16FCGR3AL48H/RL66H/RNK-92V158FV176F

Identifiers

PMID39051331
PMCPMC11270249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.